Literature DB >> 19331414

Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.

Andrew J S Knox1, Trevor Price, Michal Pawlak, Georgia Golfis, Christopher T Flood, Darren Fayne, D Clive Williams, Mary J Meegan, David G Lloyd.   

Abstract

We describe the discovery of a novel indazole-based scaffold that represents the "first-in-class" dual Hsp90/tubulin binding compound. Individual known ligands for both targets shared similar 3',4',5'-trimethoxyphenyl cores, and from this it was hypothesized that application of an integrated ligand and structure-based virtual screening (VS) workflow could yield a single scaffold with dual binding affinity. Following validation of the VS protocol, we successfully identified a novel dual inhibitor, sourced from a commercial screening collection of 160 000 compounds.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19331414     DOI: 10.1021/jm801569z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Integration-mediated prediction enrichment of quantitative model for Hsp90 inhibitors as anti-cancer agents: 3D-QSAR study.

Authors:  Kuldeep K Roy; Supriya Singh; Anil K Saxena
Journal:  Mol Divers       Date:  2010-08-26       Impact factor: 2.943

2.  Emerging topics in structure-based virtual screening.

Authors:  Giulio Rastelli
Journal:  Pharm Res       Date:  2013-03-07       Impact factor: 4.200

Review 3.  Software and resources for computational medicinal chemistry.

Authors:  Chenzhong Liao; Markus Sitzmann; Angelo Pugliese; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2011-06       Impact factor: 3.808

4.  Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain.

Authors:  Hyun-Hwi Kim; Ja-Shil Hyun; Joonhyeok Choi; Kwang-Eun Choi; Jun-Goo Jee; Sung Jean Park
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.